Propafenone

Primary Uses

Propafenone is used to restore a normal heart rhythm and maintain a steady, regular heartbeat. It belongs to a group of medicines called antiarrhythmics and works by affecting the movement of certain minerals into the heart cells, which helps stabilize the heart's electrical signals.

Conditions Treated

• Atrial Fibrillation and Flutter: It is used to prolong the time between episodes of symptomatic atrial fibrillation or atrial flutter. This is typically for patients who do not have structural heart disease, such as a history of heart failure or a recent heart attack.
• Ventricular Arrhythmias: It is prescribed to treat documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.
• Paroxysmal Supraventricular Tachycardia (PSVT): It is used to prevent the recurrence of episodes of rapid heart rate that originate in the upper chambers of the heart.

Because this medication can sometimes cause new or worsening heart rhythm problems, it is often started in a hospital setting where a healthcare provider can monitor the heart's response using an electrocardiogram (ECG).

Mechanism of Action

Propafenone belongs to a class of medicines known as antiarrhythmics. It works by affecting the way electrical impulses travel through the heart muscle.

The heart uses electrical signals to coordinate its beats. When these signals are irregular, the heart may beat too fast or in an uneven pattern. Propafenone helps manage these conditions by:

• Slowing electrical conduction: It blocks the movement of sodium into heart cells, which slows down the speed at which electrical signals move through the heart.
• Reducing excitability: It makes the heart tissue less sensitive to abnormal electrical triggers that can cause irregular rhythms.
• Stabilizing heart rhythm: By regulating these signals, the medication helps the heart maintain a normal, consistent beat.

In addition to its primary function, propafenone also has mild beta-blocking effects, which can further help in slowing the heart rate in some patients.

Common Side Effects

Many people using propafenone experience mild side effects. These may include:

• Dizziness or lightheadedness
• Nausea or vomiting
• An unusual metallic or bitter taste in the mouth
• Constipation
• Headache
• Tiredness or weakness
• Blurred vision
• Dry mouth
• Anxiety or difficulty sleeping

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• New or worsening irregular heartbeat (arrhythmia)
• Chest pain or pressure
• Shortness of breath
• Fainting or severe dizziness
• Swelling of the hands, ankles, or feet
• Yellowing of the eyes or skin (jaundice)
• Dark-colored urine
• Signs of infection, such as fever, chills, or persistent sore throat
• Unusual bruising or bleeding

Proarrhythmic Effects

Propafenone can cause new heart rhythm problems or make existing ones worse. This is known as a proarrhythmic effect. Because of this risk, treatment is often started in a hospital setting where the heart rhythm can be monitored continuously by healthcare professionals.

Heart Conditions

This medication may not be suitable for people with certain heart conditions, including:

• Congestive heart failure or a weakened heart muscle.
• Certain types of heart block or slow heart rate, unless a permanent pacemaker is in place.
• Severe low blood pressure (hypotension).
• Brugada syndrome, a genetic heart rhythm disorder.
• Recent heart attack.

Respiratory Issues

Propafenone should generally be avoided by individuals with asthma or severe chronic obstructive pulmonary disease (COPD). The medication has properties that can cause bronchospasms, which may make it difficult to breathe.

Monitoring and Lab Tests

Healthcare providers typically monitor heart function using electrocardiograms (ECGs) and check electrolyte levels, such as potassium and magnesium, before and during treatment. Liver and kidney function may also be monitored, as impairment in these organs can affect how the body processes the drug and may require dosage adjustments.

Other Precautions

Rarely, propafenone may affect blood cell counts, such as reducing white blood cells (agranulocytosis), which can increase the risk of infection. It may also cause a temporary reduction in sperm count in some individuals. Additionally, the medication can unmask certain underlying heart conditions that were not previously detected on an ECG.

Pregnancy

There are no adequate and well-controlled studies of propafenone in pregnant women. Animal studies have shown that high doses of the medication may lead to decreased fetal weight or other developmental issues. Because the effects on a human fetus are not fully known, propafenone should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the unborn baby.

If you are pregnant or planning to become pregnant, discuss the risks and benefits of this medication with your healthcare provider.

Breastfeeding

Propafenone is excreted into human breast milk. Due to the risk of serious side effects in a nursing infant, healthcare providers usually recommend either stopping breastfeeding or stopping the medication. The decision depends on how important the drug is to the mother's health.

Consult your doctor to determine the safest approach for feeding your infant while taking propafenone.

Available Forms

Propafenone is provided in two primary oral forms for the treatment of certain heart rhythm disorders:

• Immediate-release tablets: This form releases the medication into the system shortly after ingestion.
• Extended-release capsules: This form is designed to release the medication slowly over a longer period, allowing for less frequent dosing compared to the immediate-release version.

The choice between these forms depends on the specific condition being treated and the patient's clinical response. Extended-release capsules must be swallowed whole to ensure the medication is released correctly over time.

FDA Approval and Indications

Propafenone was first approved by the U.S. Food and Drug Administration (FDA) in 1989. It is currently approved for the following uses:

• Treatment of life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.
• Prevention of paroxysmal supraventricular tachycardias (PSVT), including paroxysmal atrial fibrillation and paroxysmal atrial flutter, in patients without structural heart disease.

Safety Warnings and Regulatory Considerations

The FDA-approved labeling for propafenone includes significant warnings regarding its use. Like other Class IC antiarrhythmic drugs, propafenone has the potential to cause proarrhythmic effects, which are new or worsened heart rhythm disturbances. Clinical evidence has shown that certain antiarrhythmic medications can increase the risk of death when used in patients who have had a recent heart attack or who have structural heart disease.

Propafenone is available in both immediate-release and extended-release oral formulations. It is a prescription-only medication and is not classified as a controlled substance. There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for this drug.

FDA-Approved Indications

Propafenone is approved by the U.S. Food and Drug Administration (FDA) for the following conditions:

• Treatment of life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia.
• Prevention of paroxysmal supraventricular tachycardias (PSVT), including paroxysmal atrial fibrillation and paroxysmal atrial flutter, in patients without structural heart disease.

Important Safety Warnings

The FDA requires a boxed warning for propafenone due to risks identified in clinical trials. Research has shown that certain antiarrhythmic medications can increase the risk of death or cardiac arrest in patients who have had a recent heart attack and have non-life-threatening heart rhythm issues. Consequently, propafenone is typically reserved for patients with severe, life-threatening arrhythmias.

Clinical Monitoring

The FDA labeling indicates that propafenone therapy should generally be started in a hospital environment. This allows for continuous heart rhythm monitoring to detect any potential proarrhythmic effects, which are new or worsened heart rhythm problems caused by the medication itself.